• Home
  • About
  • Drug Development Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • TSX.V: RKV
  • FSE: 7JO0
  • OTCMKTS: RKVTF

Rakovina Therapeutics Inc. Announces 2024 Financial Results and Provides Corporate Update

by Rakovina Therapeutics | Apr 30, 2025 | Uncategorized

Vancouver, British Columbia, April 30, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery announced the financial results for its...

Rakovina Therapeutics Showcases Preclinical Results of Novel AI-Discovered Cancer Therapies at AACR 2025

by Rakovina Therapeutics | Apr 29, 2025 | Uncategorized

Data highlights novel PARP1 and ATR inhibitors with progress toward next-generation therapies for hard-to-treat malignancies Vancouver, British Columbia, April 29, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing...

Rakovina Strengthens Board with Appointments of Yevgeniy Meshcherekov and David Kideckel

by Rakovina Therapeutics | Apr 29, 2025 | Uncategorized

Vancouver, British Columbia, April 29, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to announce the appointments of...

Rakovina Therapeutics Congratulates Scientific Advisor Dr. Artem Cherkasov on Global Recognition for Breakthrough AI Innovation in Drug Discovery

by Rakovina Therapeutics | Apr 22, 2025 | Uncategorized

Vancouver, British Columbia, April 22, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug discovery, is pleased to congratulate...

Rakovina Therapeutics Unveils Preclinical Data at the AACR – World’s Premier Cancer Research Forum

by Rakovina Therapeutics | Mar 27, 2025 | Uncategorized

Cutting-Edge Research Results Showcase AI-Powered Drug Discovery Vancouver, British Columbia, Mar 25, 2025 – Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence...

Next-Gen Cancer Treatment: Rakovina’s AI-Driven ATR Inhibitors Enter Preclinical Testing

by Rakovina Therapeutics | Mar 12, 2025 | Uncategorized

Harnessing generative AI to develop targeted therapies for DNA damage response, including hard-to-treat central nervous system malignancies Vancouver, British Columbia, March 12, 2025  – Rakovina Therapeutics Inc. (TSX-V: RKV)(FSE: 7JO), a biopharmaceutical company...
« Older Entries
Next Entries »

Suite 720, 999 West Broadway, Vancouver, British Columbia
Canada V5Z 1K5

Home

About

Drug Development Pipeline

News

Investors

Careers

Contact

Company Disclosure

Privacy Policy

Subscribe

To Receive Company Updates

Copyright ©2020-2026 Rakovina Therapeutics Inc. All rights reserved.  | Privacy Policy | Terms of Use |  Site by Vanooms Media